CA
CRNX icon

Continuum Advisory’s Crinetics Pharmaceuticals CRNX Stock Holding History

Continuum Advisory’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$839 – 642
2025
Q1 		$839 Buy
25
+1
+4% +$37 ﹤0.01% 1531
2024
Q4 		$1.23K Hold
24
– – ﹤0.01% 1574
2024
Q3 		$1.43K Buy
24
+11
+85% +$567 ﹤0.01% 1546
2024
Q2 		$582 Hold
13
– – ﹤0.01% 1573
2024
Q1 		$642 Buy
+13
New +$509 ﹤0.01% 1559

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Continuum Advisory's CRNX Position: Q2 2025 in Review

Continuum Advisory sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 25 shares — an estimated $839 sold.

Continuum Advisory first reported a position in CRNX in Q1 2024 and held it in 5 quarters. The position peaked at $1.43K in Q3 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Continuum Advisory reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Continuum Advisory sold 25 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $839.
  • Continuum Advisory first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Continuum Advisory's Crinetics Pharmaceuticals position peaked at $1.43K in Q3 2024.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.